BMRN | Biomarin pharmaceutical inc - Stock Value & PE Ratio Analysis

3

24

15

Average Growth

AI analysis rates BMRN with a medium value score of 3.
It is mainly due to adequate safety shown in the balance sheet, but with concerns regarding unstable operating cash flow.
Over the past 3 months, BMRN has maintained a consecutive value rating of 3.0, close to the rating of 3.4 over the past 3 years, indicating stable enterprise value.
Compared to all stocks in the Health Care sector, BMRN has a medium value rating.

BMRN Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/05/03 (Weekly Update)

BMRN Financial Forecast

Unit : USD

Update to 2025/5/4 (Quarterly Update)

BMRN Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	1.13	59.2%	20.2%	745.15M	14.8%	-2.3%	16.9%
2024Q3	0.92	87.8%	70.4%	747.31M	15.6%	4.9%	14.2%
2024Q2	0.91	97.8%	16.7%	745.74M	27.3%	4.7%	15.1%
2024Q1	0.96	77.8%	168.3%	708.66M	19.2%	6.7%	13.7%
2023Q4	0.71	18.3%	127.7%	648.83M	9.4%	-0.5%	3.2%

Update to 2025/5/7 (Quarterly Update)

BMRN Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

BMRN Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of BMRN from 2007/01 till Now

42.28%
Cumulative Return: 1.95%
Annual Return: 31.73%
Volatility: 0.06
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 3)